The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes

Postgraduate Medicine

Volumn 121, Issue 1, 2009, Pages 59-72

  Toth, Peter P ^a,b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b Sterling Rock Falls Clinic ^*  (United States)

Author keywords

Acute coronary syndrome; Antiplatelet therapy; Aspirin; Atherosclerotic plaque; Clopidogrel; Prasugrel; Secondary prevention; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PRASUGREL; TICLOPIDINE; WARFARIN; ANTITHROMBOCYTIC AGENT; PIPERAZINE DERIVATIVE; PURINERGIC P2 RECEPTOR; THIOPHENE DERIVATIVE;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLEEDING; BLOOD DYSCRASIA; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COMORBIDITY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HOSPITAL DISCHARGE; HUMAN; ISCHEMIA; LOADING DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; REVIEW; SECONDARY PREVENTION; SMOKING; STENT; STROKE; SYSTOLIC DYSFUNCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT DURATION; TREATMENT INDICATION; UNITED STATES; DRUG ANTAGONISM; DRUG EFFECT; LIFESTYLE; MORTALITY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK FACTOR;

ACUTE CORONARY SYNDROME; ASPIRIN; HUMANS; LIFE STYLE; MYOCARDIAL INFARCTION; PIPERAZINES; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, PURINERGIC P2; RECURRENCE; RISK FACTORS; THIOPHENES;

EID: 60549115629     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2009.01.1955     Document Type: Review

References (56)

1. American Heart Association. Heart Disease and Stroke Statistics - 2008 Update. Dallas, TX: American Heart Association; 2008.
2. Mehta RH, Montoye CK, Gallogly M, et al. Improving quality of care for acute myocardial infarction: The Guidelines Applied in Practice (GAP) Initiative. JAMA. 2002;287(10):1269-1276. (Pubitemid 34250481)
3. LaBresh KA, Ellrodt AG, Gliklich R, Liljestrand J, Peto R. Get with the guidelines for cardiovascular secondary prevention: pilot results. Arch Intern Med. 2004;164(2):203-209. (Pubitemid 38140408)
4. Duke Clinical Research lnstimte. 2005 CRUSADE 4th quarter results.
5. Stafford RS, Monti V, Ma J. Underutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease. PLoS Med. 2005;2(12):e353. (Pubitemid 43020988)
6. Newby LK, LaPointe KM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113(2):203-212. (Pubitemid 43754376)
7. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113(19):2363-2372.
8. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. 2007;116(7):e148-e304.
9. Grines CL, Bonow RO, Casey DE Jr, et al; American Heart Association; American College of Cardiology; Society for Cardiovascular Angiography and Interventions, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol. 2007;49(6):734-739.
10. Parchure N, Brecker SJ, Management of acute coronary syndromes. Curr Opin Crit Care. 2002;8(3):230-235. (Pubitemid 34575839)
11. Stone GW, Aronow HD. Long-term care after percutaneous coronary intervention: focus on the role of antiplatelet therapy. Mayo Clin Proc. 2006;81(5):641-652.
12. Papathanasiou A, Goudevenos J, Tselepis AD. Resistance to aspirin and clopidogrel: possible mechanisms, laboratory investigation, and clinical significance. Hellenic J Cardiol. 2007;48(6):352-363.
13. Merlini PA, Bauer KA, Oltrona L, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation. 1994;90(1):61-68. (Pubitemid 24203663)
14. Vickrey BG, Rector TS, Wickstrom SL, et al. Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. Stroke. 2002;33(4):901-906. (Pubitemid 34293565)
15. Armstrong PW, Fu Y, Chang WC, et al. Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators. Circulation. 1998;98(18):1860-1868. (Pubitemid 28509281)
16. Capewell S, Murphy NF, MacIntyre K, et al. Short-term and long- term outcomes in 133,429 emergency patients admitted with angina or myocardial infarction in Scotland, 1990-2000; population-based cohort study. Heart. 2006;92(11):1563-1570.
17. Kassem-Moussa H, Mahaffey KW, Graffagnino C, et al; SYMPHONY and 2nd SYMPHONY Investigators. Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome. Am Heart J. 2004;148(3):439-446.
18. Budaj A, Flasinska K, Gore JM, et al; GRACE Investigators. Magnitude of and risk factors for in-hospital and postdischarge stroke in patients with acute coronary syndromes: findings from a Global Registry of Acute Coronary Events. Circulation. 2005;111(24):3242-3247. (Pubitemid 40874996)
19. Etemad LR, McCollam PL. Total first-year costs of acute coronary syndrome in a managed care setting. J Manag Care Pharm. 2005;11(4):300-306.
20. Inoue T, Sohma R, Miyazaki T, Iwasaki Y, Yaguchi I, Morooka S. Comparison of activation process of platelets and neutrophils after coronary stent implantation versus balloon angioplasty for stable angina pectoris. Am J Cardiol. 2000;86(10):1057-1062.
21. Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation. 2001;103(15):1967-1971. (Pubitemid 32322224)
22. Holmes DR Jr, Kereiakes DJ, Laskey WK, et al. Thrombosis and drug-cluting stents: an objective appraisal. J Am Coll Cardiol. 2007; 50(2):109-118. (Pubitemid 47007739)
23. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, et al. 2007. Focused Update of the ACC/AHA/SCAI2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation. 2008;117(2):261-295.
24. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71-86. (Pubitemid 34073138)
25. Blann AD, Landray MJ, Lip GY. ABC of antithrombotic therapy: An overview of antithrombotic therapy. BMJ. 2002;325(7367):762-765. (Pubitemid 35193198)
26. Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation. 2001;103(2):201-206. (Pubitemid 32095403)
27. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998;339(23):1665-1671.
28. Bhatt DL, Bertrand ME, Berger PB, et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol. 2002;39(1):9-14. (Pubitemid 34059855)
29. Paradiso-Hardy FL, Angelo CM, Lanctot KL, Cohen EA. Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality. CMAJ. 2000;163(11):1441-1448.
30. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. 2006;113(7):e166-e286.
31. Chen ZM, Jiang LX, Chen YP, et al; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366(9497):1607-1621.
32. Mehla SR, Yusuf S, Peters RJ, et al; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pre- treatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527-533.
33. Steinhubl SR, Berger PB, Mann JT 3rd, et al; CREDO Investigate. Clopidogrel lor the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288(19):2411-2420.
34. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494-502.
35. Sabatine MS, Cannon CP, G ibson CM, et al; CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352(12):1179-1189.
36. Bowry AD, Brookhart MA, Choudhry NK. Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events. Am J Cardiol. 2008;101(7):960-966.
37. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005;45(2):246-251. (Pubitemid 40094733)
38. Gurbel PA, Bilden KP. Durability of platelet inhibition by clopidogrel. Am J Cardiol. 2003;91(9):1123-1125. (Pubitemid 36514934)
39. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007;153(1):66.e69-e16. (Pubitemid 44895531)
40. Savcic M, Hauen J, Bachmann F, Wyld PJ, Geudelin B, Cariou R. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost. 1999;25(suppl 2):15-19. (Pubitemid 29350286)
41. Thebault JJ, Kieffer G, Cariou R. Single-dose pharmacodynamics of clopidogrel. Semin Thromb Hemost. 1999;25(suppl 2):3-8. (Pubitemid 29350284)
42. Hochholzer W, Trenk D, Frundi D, et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselectcd cohort of candidates for percutaneous coronary intervention. Circulation. 2005;111(20):2560-2564. (Pubitemid 40740853)
43. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004; 109(25):3171-3175.
44. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol. 2005;45(8):1157-1164. (Pubitemid 40523131)
45. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J. 2007;154(2):221-231. (Pubitemid 47069129)
46. Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006;27(10):1166-1173. (Pubitemid 43752387)
47. 12 inhibitor, compared with clopidogrel in healthy humans. Br J Clin Pharmacol. 2007;63(4):421-430.
48. Wiviott SD, Trenk D, Frelinger AL, et al; PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007;116(25):2923-2932.
49. Antman EM, Wiviott SD, Murphy SA, et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel- Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol. 2008;51(21):2028-2033.
50. Wiviott SD, Braunwald E, McCabe CH, et al; TRITON-TIMI38 Investigators. Intensive oral antiplatelet therapy lor reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet. 2008;371(9621):1353-1363.
51. Murphy SA, Antman EM, Wiviott SD, et al; TRITON-TIMI 38 Investigators. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J. 2008;29(20):2473-2479.
52. Wiviott SD, Braunwald E, McCabe CH, et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-2015.
53. Biondi-Zoccai GG, Lotrionte M, Agostoni P, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J. 2006;27(22):2667-2674. (Pubitemid 44729867)
54. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation. 2006;113(24):2803-2809. (Pubitemid 44305292)
55. Watkins H, Farrall M. Genetic susceptibility to coronary artery disease: from promise to progress. Nat Rev Genet. 2006;7(3):163-173. (Pubitemid 43361528)
56. 12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation. 2005;111(25):3366-3373. (Pubitemid 40931949)